Key Information
Transthyretin amyloid cardiomyopathy (ATTR-CM) has rapidly moved from a once under-recognized infiltrative cardiomyopathy to a major focus of contemporary heart failure practice. This shift has been driven by improved diagnostic pathways, wider use of bone scintigraphy and advanced imaging, and, importantly, the emergence of disease-modifying therapies.1external link, opens in a new tab, 2)external link, opens in a new tab Yet, despite this remarkable progress, the therapeutic landscape of ATTR-CM remains incomplete. Access to disease-specific agents is still uneven across health care systems, treatment costs remain substantial, and many patients continue to experience progressive symptoms, recurrent congestion, and excess mortality even after diagnosis.3)external link, opens in a new tab Against this background, interest has grown in whether established heart failure therapies may offer incremental benefit in ATTR-CM.